Pitcairn Co. Grows Holdings in Enovis Co. (NYSE:ENOV)

Pitcairn Co. raised its position in shares of Enovis Co. (NYSE:ENOV) by 46.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,673 shares of the company’s stock after purchasing an additional 3,690 shares during the quarter. Pitcairn Co.’s holdings in Enovis were worth $512,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. UMB Bank n.a. raised its stake in Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after purchasing an additional 437 shares during the period. Pinnacle Bancorp Inc. grew its holdings in Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after buying an additional 300 shares in the last quarter. FMR LLC raised its position in shares of Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after buying an additional 484 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Enovis in the third quarter worth $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new position in shares of Enovis during the fourth quarter worth $228,000. 98.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of Enovis in a report on Wednesday.

Enovis Stock Down 3.8 %

Shares of ENOV opened at $32.52 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -14.85 and a beta of 1.86. Enovis Co. has a 1 year low of $31.00 and a 1 year high of $62.79. The business’s 50 day simple moving average is $40.90 and its 200-day simple moving average is $43.09.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. As a group, equities analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.